Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.31 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6376514 | 0.84 | CYP11B1 (0.41) | PTGS2CYP11B2CYP11B1CA1CA2 | |
| SCHEMBL11782456 | 0.77 | BCHE (0.30) | ACHE | |
| SCHEMBL395757 | 0.74 | CYP11B2 (0.41) | PTGS2CYP11B2CYP11B1TRPA1CA1 | |
| SCHEMBL29463838 | 0.74 | CYP11B2 (0.41) | PTGS2CYP11B2CYP11B1TRPA1CA1 | |
| SCHEMBL30835519 | 0.73 | PTGS2 (0.40) | PTGS2CYP11B2CYP11B1TRPA1CA1 | |
| SCHEMBL7205941 | 0.71 | PTGS2 (0.57) | PTGS2CYP11B2CYP11B1TRPA1MAOA | |
| SCHEMBL30664496 | 0.71 | PTGS2 (0.57) | PTGS2CYP11B2CYP11B1TRPA1MAOA | |
| SCHEMBL14663400 | 0.68 | PTGS2 (0.46) | PTGS2CYP11B2CYP11B1TRPA1MAOA | |
| SCHEMBL3368925 | 0.67 | — | — | |
| SCHEMBL17673043 | 0.67 | CYP11B2 (0.41) | PTGS2CYP11B2CYP11B1TRPA1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060257917-A1 | FLUORESCENT DYES, ENERGY TRANSFER COUPLES AND METHODS | MILLIPORE CORPORATION | 2006-11-16 | — | — | US | disclosed |
| US-7091348-B2 | Fluorescent dyes, energy transfer couples and methods | GUAVA TECHNOLOGIES, INC. (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1539728-A2 | FLUORESCENT DYES, ENERGY TRANSFER COUPLES AND METHODS | Guava Technologies, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040073014-A1 | Fluorescent dyes, energy transfer couples and methods | EMD MILLIPORE CORPORATION | 2004-04-15 | — | — | US | disclosed |
| WO-2004003510-A2 | FLUORESCENT DYES, ENERGY TRANSFER COUPLES AND METHODS | GUAVA TECHNOLOGIES, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060257917-A1 | FLUORESCENT DYES, ENERGY TRANSFER COUPLES AND METHODS | TIMM50, TIMM44, APEX1 | PTGS2 4031/4885CYP11B2 908/4885CYP11B1 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.